Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

336.93
Delayed Data
As of Jun 20
 +9.86 / +3.01%
Today’s Change
281.89
Today|||52-Week Range
543.55
-10.38%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$32.8B

Company Description

Regeneron Pharmaceuticals, Inc. engages in the discovery, invention, development, manufacture, and commercialization of medicines for the treatment of serious diseases. It products include the following brands: EYLEA, Dupixent, Praluent, Kevzara, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Contact Information

Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown New York 10591-6707
P:(914) 847-7000
Investor Relations:
(914) 847-5126

Employees

Shareholders

Mutual fund holders39.72%
Other institutional29.92%
Individual stakeholders25.06%

Top Executives

Leonard S. SchleiferCo-President, Chief Executive Officer & Director
George Damis YancopoulosCo-President, Director & Chief Scientific Officer
Robert E. LandryChief Financial Officer & Senior VP-Finance
Beth F. LevineSenior Vice President & Chief Compliance Officer
Daniel P. Van PlewSVP, GM-Industrial Operations & Product Supply